EFG Asset Management (Americas)’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.79M | Sell |
11,615
-1,757
| -13% | -$573K | 0.7% | 46 |
|
|
2025
Q1 | $3.61M | Sell |
13,372
-1,574
| -11% | -$425K | 0.73% | 46 |
|
|
2024
Q4 | $3.52M | Sell |
14,946
-7
| -0% | -$1.65K | 0.68% | 51 |
|
|
2024
Q3 | $4.11M | Sell |
14,953
-2,039
| -12% | -$561K | 0.8% | 43 |
|
|
2024
Q2 | $4.13M | Buy |
16,992
+6,106
| +56% | +$1.48M | 0.81% | 42 |
|
|
2024
Q1 | $1.63M | Sell |
10,886
-5,365
| -33% | -$802K | 0.5% | 61 |
|
|
2023
Q4 | $3.11M | Buy |
16,251
+794
| +5% | +$152K | 0.67% | 46 |
|
|
2023
Q3 | $2.74M | Sell |
15,457
-278
| -2% | -$49.2K | 0.66% | 49 |
|
|
2023
Q2 | $2.99M | Buy |
15,735
+556
| +4% | +$106K | 0.69% | 45 |
|
|
2023
Q1 | $3.04M | Sell |
15,179
-238
| -2% | -$47.7K | 0.73% | 45 |
|
|
2022
Q4 | $3.66M | Buy |
15,417
+275
| +2% | +$65.4K | 0.91% | 35 |
|
|
2022
Q3 | $3.03M | Buy |
15,142
+1,893
| +14% | +$379K | 0.77% | 44 |
|
|
2022
Q2 | $1.93M | Sell |
13,249
-3,489
| -21% | -$509K | 0.46% | 59 |
|
|
2022
Q1 | $2.73M | Buy |
+16,738
| New | +$2.73M | 0.51% | 55 |
|
|
2021
Q3 | – | Sell |
-26,187
| Closed | -$4.44M | – | 136 |
|
|
2021
Q2 | $4.44M | Buy |
26,187
+1,747
| +7% | +$296K | 0.82% | 44 |
|
|
2021
Q1 | $3.45M | Buy |
24,440
+1,020
| +4% | +$144K | 0.71% | 52 |
|
|
2020
Q4 | $3.04M | Buy |
23,420
+2,341
| +11% | +$304K | 0.62% | 58 |
|
|
2020
Q3 | $3.07M | Buy |
+21,079
| New | +$3.07M | 0.69% | 57 |
|